Investors Careers FAQ Contact COMPANY TECHNOLOGIES PIPELINE NEWS & EVENTS CLINICAL TRIALS ViaCyte’s Product Pipeline PEC-Direct (VC-02) ViaCyte’s PEC-Direct product candidate is in clinical development for patients with type 1 diabetes with the highest risk of life-threatening acute complications. For PEC-Direct, the pouch is designed to allow blood vessels to enter the device and directly interact with the implanted PEC-01 cells. The direct vascularization of the implanted cells is intended to allow for robust and consistent engraftment but will necessitate the use of immune suppression therapy because the implanted cells are not hidden from the immune system. Patients who receive PEC-Direct must take immunosuppressants to protect the cells, making it suitable only for people with high-risk type 1 diabetes. The PEC-Direct product candidate is being developed for type 1 diabetes patients who have hypoglycemia unawareness and/or extreme glycemic lability. It is estimated that about 140,000 people in the United States and Canada have high-risk type 1 diabetes. In addition to a potentially unlimited supply of cells for implantation, the PEC-Direct approach has other potential advantages relative to cadaver islet transplants such as delivering a more consistent product preparation under quality-controlled cGMP conditions and a more straightforward and potentially safer mode of administration. The PEC-Direct product candidate is in clinical development for patients with high-risk type 1 diabetes. COMPANY TECHNOLOGIES PIPELINE NEWS & EVENTS CLINICAL TRIALS CONTACT Copyright 2021 ViaCyte, Inc. All Rights Reserved Terms of Service Privacy Policy We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT

Investors Careers FAQ Contact COMPANY TECHNOLOGIES PIPELINE NEWS & EVENTS CLINICAL TRIALS Advocacy Partners ViaCyte has multiple key relationships with advocacy organizations. These groups have supported the research and development of ViaCyte’s breakthrough cell replacement product candidates for insulin-requiring diabetes. If you would like more information on collaborating with ViaCyte, please contact us for further information. Contact Us Stem cell research and development at ViaCyte is seeking to change the way type 1 diabetes is treated. The video was produced by CIRM. Our latest news Dec 03, 2021 Press Releases ViaCyte Chief Scientific Officer to Deliver Keynote Address at JDRF Mission Summit Read More Sign up for updates To have our press releases and major updates sent to you, please provide your name and email address. COMPANY TECHNOLOGIES PIPELINE NEWS & EVENTS CLINICAL TRIALS CONTACT Copyright 2021 ViaCyte, Inc. All Rights Reserved Terms of Service Privacy Policy We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT